Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma

Thenmalar Vadiveloo; Graham Scotland; Corinne Booth; Clare Robertson; Moira Cruickshank; Lorna Aucott; Charlotte Kennedy; Paul Manson; Gavin Preston; Miriam Brazzelli

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma

Thenmalar Vadiveloo, Graham Scotland, Corinne Booth, Clare Robertson, Moira Cruickshank, Lorna Aucott, Charlotte Kennedy, Paul Manson, Gavin Preston, Miriam Brazzelli^* (Corresponding Author)

^*Corresponding author for this work

Research output: Book/Report › Commissioned Report

Abstract

Evidence Review Group report in support of NICE STA Programme.

Original language	English
Place of Publication	London
Publisher	Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Number of pages	106
Publication status	Published - 15 Mar 2022

Bibliographical note

Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135434

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://njl-admin.nihr.ac.uk/document/download/2040067Licence: Unspecified

Cite this

Vadiveloo, T., Scotland, G., Booth, C., Robertson, C., Cruickshank, M., Aucott, L., Kennedy, C., Manson, P., Preston, G., & Brazzelli, M. (2022). Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma. Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. https://njl-admin.nihr.ac.uk/document/download/2040067

Vadiveloo, T , Scotland, G, Booth, C, Robertson, C , Cruickshank, M, Aucott, L, Kennedy, C, Manson, P, Preston, G & Brazzelli, M 2022, Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma. Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence, London. <https://njl-admin.nihr.ac.uk/document/download/2040067>

@book{26d9cb32d2144f8ebdc0f71a4b9f462c,

title = "Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma",

abstract = "Evidence Review Group report in support of NICE STA Programme. ",

author = "Thenmalar Vadiveloo and Graham Scotland and Corinne Booth and Clare Robertson and Moira Cruickshank and Lorna Aucott and Charlotte Kennedy and Paul Manson and Gavin Preston and Miriam Brazzelli",

note = "Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135434",

year = "2022",

month = mar,

day = "15",

language = "English",

publisher = "Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma

AU - Vadiveloo, Thenmalar

AU - Scotland, Graham

AU - Booth, Corinne

AU - Robertson, Clare

AU - Cruickshank, Moira

AU - Aucott, Lorna

AU - Kennedy, Charlotte

AU - Manson, Paul

AU - Preston, Gavin

AU - Brazzelli, Miriam

N1 - Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135434

PY - 2022/3/15

Y1 - 2022/3/15

N2 - Evidence Review Group report in support of NICE STA Programme.

AB - Evidence Review Group report in support of NICE STA Programme.

UR - https://www.nice.org.uk/guidance/ta894

M3 - Commissioned Report

BT - Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma

PB - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

CY - London

ER -

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this